NO176179B - Analogifremgangsmåte for fremstilling av nye terapeutisk aktive 2-substituerte N,N'-di(trimetoksybenzoyl)piperaziner - Google Patents
Analogifremgangsmåte for fremstilling av nye terapeutisk aktive 2-substituerte N,N'-di(trimetoksybenzoyl)piperaziner Download PDFInfo
- Publication number
- NO176179B NO176179B NO894037A NO894037A NO176179B NO 176179 B NO176179 B NO 176179B NO 894037 A NO894037 A NO 894037A NO 894037 A NO894037 A NO 894037A NO 176179 B NO176179 B NO 176179B
- Authority
- NO
- Norway
- Prior art keywords
- trimethoxybenzoyl
- piperazine
- nmr
- ppm
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 7
- -1 2-Substituted N, N'-Di (Trimethoxybenzoyl) Piperazines Chemical class 0.000 title claims description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- SOUPGWGAPDMYFM-UHFFFAOYSA-N (1,4-dibenzylpiperazin-2-yl)methanol Chemical compound C1CN(CC=2C=CC=CC=2)C(CO)CN1CC1=CC=CC=C1 SOUPGWGAPDMYFM-UHFFFAOYSA-N 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 150000004885 piperazines Chemical class 0.000 claims description 5
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003610 charcoal Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- MYNRDUPGBPOWQT-IDTAVKCVSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-[[3-hydrazinylpropyl(methyl)amino]methyl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CN(CCCNN)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MYNRDUPGBPOWQT-IDTAVKCVSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- MJJXWPHZDBIHIM-UHFFFAOYSA-N 5-isocyanato-1,2,3-trimethoxybenzene Chemical compound COC1=CC(N=C=O)=CC(OC)=C1OC MJJXWPHZDBIHIM-UHFFFAOYSA-N 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- BXIGZIXGNMVVFJ-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl 2,2-dimethylpropanoate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CC(COC(=O)C(C)(C)C)N(CC2)C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)=C1 BXIGZIXGNMVVFJ-UHFFFAOYSA-N 0.000 description 1
- ZBRLGJYJSHQDOY-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl 2-ethylbutanoate Chemical compound CCC(CC)C(=O)OCC1CN(C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)CCN1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZBRLGJYJSHQDOY-UHFFFAOYSA-N 0.000 description 1
- ZVGSBMSQLRSOHN-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl 3,3-dimethylbutanoate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CC(COC(=O)CC(C)(C)C)N(CC2)C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)=C1 ZVGSBMSQLRSOHN-UHFFFAOYSA-N 0.000 description 1
- KRGMLTJKLQEHOZ-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl acetate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CC(COC(C)=O)N(CC2)C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)=C1 KRGMLTJKLQEHOZ-UHFFFAOYSA-N 0.000 description 1
- IWRWPHXCANDKPP-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl butanoate Chemical compound CCCC(=O)OCC1CN(C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)CCN1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 IWRWPHXCANDKPP-UHFFFAOYSA-N 0.000 description 1
- BLDZWCUVWBMDLL-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl cyclohexanecarboxylate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CC(COC(=O)C3CCCCC3)N(CC2)C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)=C1 BLDZWCUVWBMDLL-UHFFFAOYSA-N 0.000 description 1
- OYHTTZDJDLVHDP-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl decanoate Chemical compound CCCCCCCCCC(=O)OCC1CN(C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)CCN1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 OYHTTZDJDLVHDP-UHFFFAOYSA-N 0.000 description 1
- URTKPOVVQZNBPW-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl hexanoate Chemical compound CCCCCC(=O)OCC1CN(C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)CCN1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 URTKPOVVQZNBPW-UHFFFAOYSA-N 0.000 description 1
- RIPBNIBRYTXDLA-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC1CN(C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)CCN1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 RIPBNIBRYTXDLA-UHFFFAOYSA-N 0.000 description 1
- HRAVCYOABUOCGK-UHFFFAOYSA-N [1,4-bis(3,4,5-trimethoxybenzoyl)piperazin-2-yl]methyl octanoate Chemical compound CCCCCCCC(=O)OCC1CN(C(=O)C=2C=C(OC)C(OC)=C(OC)C=2)CCN1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 HRAVCYOABUOCGK-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 1
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- ISYGJWPNTJUYRF-UHFFFAOYSA-N piperazin-2-ylmethyl cyclohexanecarboxylate Chemical compound C1CCCCC1C(=O)OCC1CNCCN1 ISYGJWPNTJUYRF-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Denne oppfinnelse angår en fremgangsmåte for fremstilling av piperazin-derivater med den generelle formel I:
hvor Z utgjør en substituent A eller NH-A, hvori A utgjør en rett eller forgrenet alkylkjede med fra 1 til 17 karbonatomer;
en cykloheksylgruppe eller fenyl, som kan være substituert med klor eller tre metoksygrupper.
I henhold til oppfinnelsen består fremgangsmåten i
omsetning av en forbindelse med formel A-C=0, når Z = A, eller
Cl
A-N=C=0 når Z = NH-A, hvori A er som ovenfor definert, med N,N'-dibenzyl-2-hydroksymetylpiperazin. Omsetningen utføres hensiktsmessig i nærvær av trietylamin i et aprotisk oppløsningsmiddel, så som dietyleter, tetrahydrofuran, benzen eller toluen, ved romtemperatur når reaksjonen utføres med A-C=0,
Cl
eller i benzen eller toluen, ved 80°C, når reaksjonen utføres med A-N=C=0.
Det oppnådde, tilsvarende, trisubstituerte piperazin med formel II: hydrogenolyseres deretter i nærvær av Pd/kull (i etanol) som fører til det monosubstituerte piperazin med formel III:
som di-N-substitueres ved behandling med 3,4,5-trimetoksy-benzoylklorid i benzen, i nærvær av trietylamin og ved romtemperatur for å gi I.
Eksempel 1
N,N'-di-(3',4',5'-trimetoksybenzoyl) -2-cykloheksylkarbonyloksy-metylpiperazin
Trinn A
Fremstilling av N,N'-dibenzyl 2-cykloheksylkarbonyl-
oksymetylpiperazin (II,
En oppløsning av 2 g (6,8 mmol) N,N'-dibenzyl-2-hydroksymetylpiperazin i 30 ml tørr benzen og 1 ml trietylamin ble dråpevis tilsatt til 1,1 g (6,8 mmol) cykloheksankarbonylklorid i 10 ml benzen. Etter omrøring over natten ved romtemperatur ble oppløsningsmidlene fjernet under redusert trykk og det rå residuum behandlet med CHC13, vasket med H20, fortynnet NaHC03 og deretter med H20. Det organiske lag ble deretter tørket (MgSOJ , inndampet og kromatografert på en silikagelkolonne under bruk av dietyleter/petroleter (10:90, volumdeler) som eluent. Denne rensingen førte til 1,87 g (68%) av tittelforbindelsen som en olje.
IR (film): 3090, 3070, 3030 (ArC-H), 2940, 2860, 2810 (C-H), 1735 (C-0) , 1600 (ArC = C) cm"<1>.
<X>H NMR (80 MHZ, CDC13, HMDS) S ppm: 7,27 (stor s, 10H, ArH) , 4,55 (m, 2H, CH2OC = O) , 4,12-3,25 (m, 5H, CH2ø + CH-N) , 2,95-2,02 (m, 7H, CH2 piperazin + CH-C = O) , 1,72 (m, 4H,
CH2-C-C = O) , 1,25 (m, 6H, CH2 cykloheksyl) .
Trinn B
Fremstilling av 2-cykloheksylkarbonyloksymetyl
piperazin (III,
En oppløsning av 1,5 g (3,7 mmol) av forbindelsen fremstillet i Trinn A og 50 mg Pd(10%)/kull i 50 ml etanol ble behandlet med H2 ved et trykk på 2,8 bar under omrøring ved 40°C over natten. Etter filtrering ble etanolen inndampet under redusert trykk og det rå residuum renset på en silikagelkolonne ved bruk av MeOH/CHCl3 (5:95, volumdeler) som eluent. Dette ga 0,75 g (90%) av tittelforbindelsen som et meget hygroskopisk produkt.
IR (film): 3340 (N-H) , 2960, 2860 (C-H), 1730 (C = O) cm"<1>.
<X>H NMR (80 MHZ, CDCl3, HMDS) 6 ppm: 3,95 (d, 2H, CH2OC = 0), 3,72-3,27 (m, 1H, CH-N), 3,45 (s, 2H, forsvinner med D20, NH) , 3,25-2,27 (m, 7H, CHC=0 + CH2 piperazin), 1,62 (m, 4H,
CH2-C-C = 0), 1,2 (m, 6H, CH2, cykloheksyl).
Trinn C
Fremstilling av N,N'-di-(3',4',5'-trimetoksybenzoyl)-
2-cykloheksylkarbonyloksymetylpiperazin (I,
En oppløsning av 0,5 g (2,2 mmol) av forbindelsen fremstillet i Trinn B i 30 ml tørr benzen og 1,5 ml trietylamin, ble dråpevis tilsatt til 1 g (4,6 mmol) 3,4,5-trimetoksy-benzoylklorid i 10 ml tørr benzen. Blandingen ble holdt ved romtemperatur under omrøring over natten. Overskuddet av acylklorid ble deretter dekomponert ved tilsetning av 1 ml EtOH. Etter fordampning av oppløsningsmidlene under redusert trykk, ble residuet behandlet med CHC13, vasket med H20, fortynnet NaHC03 og deretter med H20. Etter tørking (MgS04) og fordampning av kloroformen, førte rensing på en silikagelkolonne ved bruk av MeOH/CHCl3 (0,5:99,5, volumdeler) til 1,1 g (74%) av tittelforbindelsen som en voks.
IR (film): 3050, 3000 (ArC-H), 2940, 2860 (C-H), 1720 (C = O ester) , 1650 (C = O amid) , 1585 (ArC = C) cm"<1>.
<X>H NMR (60 MHZ, CDC13, HMDS), S ppm: 6,57 (s, 4H, ArH) , 4,83
(d, 2H, CH2OC = 0), 4,45-3,97 (m, 3H, O = C NCH2-CH-NC = O) , 3,86 (stor s, 18H, CH30), 3,5-2,66 (m, 4H, CH2NC = O), 2,6-2,23 (m, 1H, CHC = O) , 1,93-0,9 (m, 10H, CH2 cykloheksyl).
EKSEMPEL 2
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-tert-butyl-karbonyloksy-metylpiperazin Z = C(CH3)3
Tittelforbindelsen ble oppnådd som beskrevet i Eksempel
1, Trinn A, B, C ved å gå ut fra 2,2-dimetyl-propanoylklorid i stedet for cykloheksankarbonylklorid, som en voksaktig forbindelse.
IR (film): 3060 (ArC-H), 2960, 2840 (C-H), 1730 (C = O ester), 1640 (C = O amid) , 1585 (ArC = C) cm"<1>.
<:>H NMR (60 MHz, CDC13, HMDS) S ppm: 6,63 (s, 4H, ArH), 4,93-4,5 (m, 2H, CH2OC = O) , 4,43-3,96 (m, 3H, O = CNCH2 CHNC = 0), 3,86 (s, 18H, CH30) , 3,5-2,8 (m, 4H, CH2NC = O) , 1,06 (s, 9H, CH3) .
Eksempel 3
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-n-butanoyloksymetyl piperazin Z = (CH2)2CH3
Tittelforbindelsen ble oppnådd som beskrevet i Eksempel
1, Trinn A, B, C ved å gå ut fra n-butanoylklorid, som en
olje.
IR (Film): 3080 (ArC-H), 2930-2860 (C-H), 1720 (C = 0 ester), 1640 (C = 0 amid), 1585 (ArC = C) cm"<1>.
<X>H NMR (80 MHZ, CDC13, HMDS) 6 ppm: 6,62 (s, 4H, ArH), 4,66 (m, 2H, CH2OC = 0), 4,55-4,05 (m, 3H, O = CNCH2CHNC = 0), 3,85 (stor s, 18H, CH30) , 3,52-2,8 (m, 4H, CH2NCO) , 2,3 (m, 2H, CH2C0) , 1,77-1,35 (m, 2H, CH2-C-C = 0) , 0,87 (t, 3H, CH3) .
Eksempel 4
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-n-oktanoyloksymetyl piperazin Z = (CH2)6CH3
Tittelforbindelsen ble oppnådd som beskrevet i Eksempel 1, Trinn A, B, C ved å gå ut fra n-oktanoylklorid. Viskøs forbindelse.
IR (film): 3060, 3000 (ArC-H), 2940, 2860 (C-H), 1735 (C = O ester), 1640 (C = 0 amid), 1585 (ArC = C) cm"<1>.
<X>H NMR (80 MHZ, CDC13, HMDS) S ppm: 6,62 (s, 4H, ArH), 4,85-4,05 (m, 5H, CH2OC = 0 + O = CNCH2-CHNCO) , 3,77 (s, 18H, CH30) , 3,57-2,7 (m, 4H, CH2NC = O) , 2,2 (t, 2H, CH2C = 0), 1,52 (m, 2H, CHz-C-C = O) , 1,33 (stor s, 8H, (CH2)4), 0,82 (t, 3H, CH3) .
Eksempel 5
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-n-dekanoyloksymetyl piperazin Z = (CH2)8CH3
Tittelforbindelsen ble oppnådd som beskrevet i Eksempel 1, Trinn A, B, C ved å gå ut fra n-dekanoylklorid. Viskøs forbindelse.
IR (film): 3060 (ArC-H), 2920, 2850 (C-H), 1740 (C = 0 ester), 1635 (C = O amid) , 1580 (AC < C) Cl"<1>.
<X>H NMR (80 MHz, CDC13, HMDS) 5 ppm: 6,6 (s, 4H, ArH), 4,6 (m, 2H, CH20C = 0) , 4,45-3,97 (m, 3H, 0 = CNCH2-CH-NC = O) , 3,87 (s, 18H, CH30) , 3,65-2,85 (m, 4H, CH2NC = 0), 2,12 (t, 2H, CH2C = O) , 1,42 (m, 2H, CH2-C-C = O) , 0,75 (t, 3H, CH3) .
Eksempel 6
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-oktadekanoyloksymetyl piperazin Z = (CH2)i6CH3
Tittelforbindelsen ble oppnådd som beskrevet i Eksempel 1, Trinn A, B, C ved å gå ut fra oktadekanoylklorid. Viskøs olje.
IR (film): 3020 (ArC-H), 2940, 2870 (C-H), 1725 (C = O ester), 1650 (C = 0 amid) , 1595 (ArC = C) cm"<1>.
<J>H NMR (80 MHz, CDCl3, HMDS) S ppm: 6,57 (s, 4H, ArH), 4,75-4,0 (m, 5H, CH2OC = 0 + 0 = CNCH2CHNC = O) , 3,87 (s, 9H, CH30) , 3,48-2,75 (m, 4H, CH2NC = O) , 2,22 (t, 2H, CH2C = 0) , 1,47 (m, 2H, CH2-C-C = 0), 1,21 (stor s, 28H, (CH2)U), 0,77 (t, 3H, CH3) .
Eksempel 7
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-ortoklorbenzoyloksymetyl
piperazin
Tittelforbindelsen ble oppnådd som beskrevet i Eksempel 1, Trinn A, B, C ved å gå ut fra 2-klorbenzoylklorid. Oljeaktig produkt.
IR (film): 3070, 3020 (ArC-H), 2930, 2860 (C-H), 1720 (C = 0 ester), 1630 (C = 0 amid), 1590 (ArC = C) cm"<1>.
<X>H NMR (60 MHz, CDC13, HMDS) 6 ppm: 7,63-7,13 (m, 4H,- klorfenyl H), 6,56. (d, 4H, trimetoksyfenyl Ar-H), 4,83 (m, 2H,
CH20C = 0), 4, 63-3,96 (m, 3H, 0 = CNCH2-CHNC = 0), 3,8 (s, 18H, CH30) , 3,5-2,73 (m, 4H, CH2NC = O) .
Eksempel 8
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-(n-butyl)-karbamoyloksymetylpiperazin Z : NH-(CH2) 3-CH3
Trinn A
Fremstilling av N,N'-dibenzy1 2-N"-(n-butyl)-karbamoyloksy-metylpiperazin (II, Z = NH(CH2) <,CH3)
En blanding av 10 g (34 mmol) N,N'-dibenzyl 2-hydroksymetyl piperazin, 10 g (102 mmol) n-butyl-isocyanat og 15 ml trietylamin i 100 ml tørr benzen, ble kokt under omrøring og tilbakeløpskjøling i 48 timer. Etter fordampning av oppløsningsmidlene, ble det rå residuum behandlet med CHC13, vasket med H20, fortynnet NaHC03 og deretter med H20. Kloroformlaget ble tørket (MgSOJ , konsentrert under redusert trykk og renset på en silikagelkolonne under bruk av dietyleter/petroleter (10:90, volumdeler) som eluent for å gi 11,7 g (87%) av tittelforbindelsen som en olje.
IR (film): 3330 (N-H), 3080, 3060, 3020 (ArC-H), 2940, 2860 (C-H), 1720 (C = O uretan).
<X>H NMR (80 MHz, CDC13, HMDS) S ppm: 7,27 (stor s, 10H, ArH), 4,63 (m, 1H, NH), 4,37 (m, 2H, CH2OC =0), 4,02 og 3,63 (2 s, 4H, CH20) , 3,28-2,45 (m, 9H, piperazin + CH2NC = 0) , 1,52-1,02 (m, 4H, (CH2)2), 0,82 (t, 3H, CH3) .
Trinn B og C
Tittelforbindelsen ble oppnådd som beskrevet i Eksempel 1, Trinn B og C. Den besto av hvite krystaller, smp. 90°C.
IR (Nujol): 3340 (N-H), 1720 (C = 0 metan), 1635 (C = 0 amid), 1590 (ArC = C) cm"<1>.
<X>H NMR (80 MHz, CDCl3, HMDS) S ppm: 6,6 (s, 4H, ArH), 4,72 (m, 2H, CH20C = 0) , 4,65-3,92 (m, 4H, 0 = CNCH2CHNC = 0 + NH) , 3,87 (stor s, 18H, CH30) , 3,42-2,7 (m, 6H, CH2NC = O) , 1,3 (m, 4H, (CH2)2) , 0,8 (t, 3H, CH3) .
Eksempel 9
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-(3',4',5'-trimetoksyfenyl)-karbamoyloksymetylpiperaz in
Tittelforbindelsen ble oppnådd som beskrevet i Eksempel 8, for Trinn A ved å gå ut fra ekvimolare mengder N,N'-dibenzyl 2-hydroksymetylpiperazin og 3,4,5-trimetoksyfenyl-isocyanat i stedet for n-butyl-isocyanat. Trinnene B og C var som i Eksempel 1, Trinn B og C. Tittelforbindelsen utgjorde et blekgult faststoff, smp. = 122°C.
IR (Nujol): 3300 (N-H), 1735 (C = 0 uretan), 1630 (C = 0 amid) , 1590 (ArC = C) cm"<1>.
<X>H NMR (80 MHz, CDC13, HMDS) S ppm: 6,80 (m, 1H, NH), 6,62 (m, 6H, ArH), 4,9-4,52 (m, 2H, CH20C = O) , 4,47-3,97 (m, 3H,
O = CNCH2-CHNC = 0) , 3,58-2,75 (m, 4H, CH2NC = 0) .
Etter samme fremgangsmåte som beskrevet i Eksempel 1, trinn A, B, C, ble de følgende forbindelser fremstillet (kun endringer av <X>H NMR-spektrene er angitt): Eksempel 10 N,N' -di-(3',4',5'-trimetoksybenzoyl)-2-(2'-etyl)-butanoyloksy-metylpiperaz in
smp. = 170,2°C.
<X>H NMR S ppm: 2,12 (kvintett, 1H, CHEt2) , 1,47 (kvintett, 4H, CH2CH3) , 0,77 (t, 6H, CH3) .
Eksempel 11
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-n-heksanoyloksymetyl piperazin Z = -(CH2)^CH3
Voksaktig faststoff. <X>H NMR 6 ppm: 2,27 (m, 2H, CH2C = 0) , 1,51 (m, 2H, CH2-C-C = 0) , 1,25 (m, 4H, CH2) , 0,77 (t, 3H, CH3) .
Eksempel 12
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-acetyloksymetyl piperazin Z = -CH3
smp. = 59°C. <X>H NMR S ppm: 1,93 (s, 3H, CH3C = 0) .
Eksempel 13
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-tert-butyl acetyloksy-metylpiperazin Z = -CH2C(CH3)3
smp. = 86,6°C. <X>H NMR «5 ppm: 2,05 (s, 2H, CH2C = O) , 0,92 (s, 9H, CH3) .
Ifølge den samme fremgangsmåte som beskrevet i Eksempel 8, Trinn A, B, C, ble de følgende forbindelser fremstillet (kun endringer av <X>H NMR-spektrene er angitt): Eksempel 14 N,N'-di-(3'f 4•,5'-trimetoksybenz oy1)-2-N"-(1'-etyl)-propy1 karbamoyloksymetylpiperaz in
smp. = 90,2°C. <X>H NMR S ppm: 3,55-2,92 (m, 5H,
CH2NC = O + CHNCOO) , 1,37 (m, 4H, CH2CH3) , 0,82 (t, 6H, CH3) .
Eksempel 15
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-tert-butyl karbamoyloksymetylpiperazin Z = -NH-C(CH3)3.
Viskøs forbindelse. <X>H NMR S ppm: 1,20 (s, 9H, CH3) .
Eksempel 16
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-tert-amyl karbamoyloksymetylpiperazin Z = -NH-CH2-C(CH3) 3
smp. = 80°C. <X>H NMR S ppm: 0,80 (s, 9H, CH3) .
Eksempel 17
N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-ortoklorfenyl
karbamoyloksymetylpiperaz in
smp. = 115°C. <l>H NMR S ppm: 7,3 og 6,7 (2 s, 4H, C6HA) , 6,67-6,42 (m, 4H, C6H2) . Eksempel 18 N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-(1'-metyl)-butyl karbamoyloksymetylpiperaz in smp. = 78°C. <X>H NMR S ppm: 1,27 (m, 4H, CH2) , 1,02 (d, 3H, CH3CH) , 0,85 (t, 3H, CH3) . Eksempel 19 N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-(l',2',2'-trimetyl)-propyl-karbamoyloksymetylpiperazinsmp. = 86°C. <X>H NMR S ppm: 0,92 (m, 3H, CH3CH) , 0,79 (s, 9H, CH3C) . Eksempel 20 N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-(3'-metyl)-butyl karbamoyloksymetylpiperazin smp. = 71°C. <X>H NMR S ppm: 2,17-1,80 (m, 1H, CH(CH3)2), 1,27 (m, 2H, CH2) , 0,80 (d, 6H, CH3) . Eksempel 21 N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-(1',3'-dimetyl)-butyl karbamoyloksymetylpiperazin smp. = 76°C. <4>i NMR 5 ppm: 2,35-1,91 (m, 1H, CH(CH3)2), 1,18 (m, 2H, CH2) , 0,98 (d, 3H, CH3-C-N) , 0,78 (d, 6H, CH3) . Eksempel 22 N,N'-di-(3',4',5'-trimetoksybenzoyl)-2-N"-(2'-metyl)-butyl karbamoyloksymetylpiperazin
smp. = 70°C. <X>H NMR S ppm: 1,70 (m, 1H, CH) , 1,22 (m, 2H, CH2) , 0,85 (m, 6H, CH3) .
Toksikologi
Forbindelsene fremstillet i henhold til oppfinnelsen ble gitt til mus per os for bestemmelse av akutt LD50. For samtlige forbindelser var LD50 over 700 mg/kg.
Farmakologi
En bekreftelse på den farmasøytiske betydning av de nye forbindelsene gir det følgende farmasøytiske forsøk: Hemming av blodplateaggregasion hos New Zealand- kaniner
Forsøket ble utført på blodplater med plasma fra New Zealand-kaniner.
Blodprøver ble tatt fra ørearterien og anbragt i citrat-buffer (3,8%; pH 7,4); blodet ble sentrifugert videre i 15 minutter ved 1200 RPM.
Testforbindelsen ble oppløst i DMSO, deretter helt over i blodplaterikt plasma i 1 minutt, hvoretter en dose på 2,5 nM PAF ble tilsatt.
Bestemmelsen ble gjort på et Cronolog Coultronics apparat, som bestemmer den prosentuelle transmisjon ved toppens maksimumshøyde før desaggregasjonen.
Den prosentuelle variasjon av hemmingen med hensyn til den prosentuelle transmisjon, ble beregnet (kontroll: ren
DMSO).
Denne fremgangsmåte er utførlig beskrevet i LABORATORY INVESTIGATIONS, Vol. 41, No. 3, p. 275, 1979, Jean-Pierre Cazenave, Jacques Benveniste & J. Fraser Mustard, "Aggregation of rabbits platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs".
Resultatene viser at forbindelsene hemmer aggregasjonen indusert av 2,5 nM PAF. Ni forsøk gjort på ni forskjellige kaniner tillot oss å beregne IC50 av de forskjellige forbindelser ved lineær regresjon.
Verdiene for IC50 på blodplate var som følger:
Eksempel 1 : 2,80 .10"<7>
Eksempel 2 : 1,00 .10"<7>
Eksempel 3 : 3,60 .10"<6>
Eksempel 4 : 3,14 .IO"<7>
Eksempel 5 : 2,82 . IO"6
Eksempel 6 : 4,5 . IO"5
Eksempel 7 : 1,69 . IO"7
Eksempel 8 : 2,41 .IO"<7>
Eksempel 9 : 1,38 . IO"5
Eksempel 10 : 7,12 .IO"<8>
Eksempel 11 : 4,97 .IO"6
Eksempel 12 : 4,3 .IO"<7>
Eksempel 13 : l,21<v> .IO"<7>
Eksempel 14 : 1,34 .IO"<7>
Eksempel 15 : 1,34 .IO"<7>
Eksempel 16 : 1,05 .IO"<6>
Eksempel 17 : 2,12. IO"5
Eksempel 18 : 1,04 .IO"7
Eksempel 19 : 1,69 .IO"<7>
Eksempel 20 : 1,37 .IO"<7>
Eksempel 21 : 2,82 . IO"7
Eksempel 22 : 4,73 .IO"<7>
Ved human terapeutisk anvendelse utgjør virksomme døgn-doser 1-50 mg/kg ved oral administrasjon (tabletter eller gelatinkapsler inneholdende for eksempel 50 mg eller 100 mg per enhetsdose) eller 0,1 til 5 mg/kg ved i.v. administrasjon (enhetsdoser på 5 til 100 mg i individuelle ampuller).
Claims (1)
- Analogifremgangsmåte for fremstilling av terapeutiskaktive piperazin-derivater med den generelle formelhvor Z utgjør en substituent A eller NH-A, hvori A utgjør en rett eller forgrenet alkylkjede med fra 1 til 17 karbonatomer; en cykloheksylgruppe eller fenyl, som kan være substituert med klor eller tre metoksygrupper,karakterisert ved følgende trinn a) omsetning av en forbindelse med formelnår Z = A, eller A-N=C=0 når Z = NH-A,hvori A er som ovenfor definert, med N,N'-dibenzyl-2-hydroksymetylpiperazin i nærvær av trietylamin i et aprotisk oppløs-ningsmiddel, ved romtemperatur når reaksjonen utføres medeller i benzen eller toluen, ved 80°C, når reaksjonen utføres medA-N=C=0; b) hydrogenolyse av det tilsvarende oppnådde trisubstituerte piperazin med formel II:i nærvær av Pd/kull (i etanol) som fører til det monosubstituerte piperazin med formel III:og c) behandling av forbindelsen (III) med 3,4,5-trimetoksy-benzoylklorid i benzen, i nærvær av trietylamin og ved romtemperatur for å gi piperazin-derivater med den generelle formel I.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888823776A GB8823776D0 (en) | 1988-10-11 | 1988-10-11 | New 2-methoxycarbonyl sustituted n n'-di-(trimethoxybenzoyl)piperazines |
Publications (4)
Publication Number | Publication Date |
---|---|
NO894037D0 NO894037D0 (no) | 1989-10-10 |
NO894037L NO894037L (no) | 1990-04-17 |
NO176179B true NO176179B (no) | 1994-11-07 |
NO176179C NO176179C (no) | 1995-02-15 |
Family
ID=10644989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO894037A NO176179C (no) | 1988-10-11 | 1989-10-10 | Analogifremgangsmåte for fremstilling av nye terapeutisk aktive 2-substituerte N,N'-di(trimetoksybenzoyl)piperaziner |
Country Status (33)
Country | Link |
---|---|
US (1) | US4927825A (no) |
JP (1) | JPH0635451B2 (no) |
KR (1) | KR970004913B1 (no) |
AR (1) | AR245111A1 (no) |
AT (1) | AT395422B (no) |
AU (1) | AU619146B2 (no) |
BE (1) | BE1003518A3 (no) |
CA (1) | CA1319692C (no) |
CH (1) | CH679858A5 (no) |
DE (1) | DE3933882C2 (no) |
DK (1) | DK500489A (no) |
DZ (1) | DZ1366A1 (no) |
ES (1) | ES2018404A6 (no) |
FI (1) | FI96855C (no) |
FR (2) | FR2637592B1 (no) |
GB (2) | GB8823776D0 (no) |
GR (1) | GR1000359B (no) |
HK (1) | HK47492A (no) |
IE (1) | IE61621B1 (no) |
IN (1) | IN173326B (no) |
IT (1) | IT1237087B (no) |
LU (1) | LU87605A1 (no) |
MA (1) | MA21651A1 (no) |
MY (1) | MY105852A (no) |
NL (1) | NL8902519A (no) |
NO (1) | NO176179C (no) |
NZ (1) | NZ230928A (no) |
OA (1) | OA09429A (no) |
PT (1) | PT91940B (no) |
SE (1) | SE505222C2 (no) |
SG (1) | SG40592G (no) |
TN (1) | TNSN89109A1 (no) |
ZA (1) | ZA897553B (no) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823775D0 (en) * | 1988-10-11 | 1988-11-16 | Scras | New 2-carbonyl substituted n n'-di-(trimethoxybenzoyl)piperazines |
GB8908587D0 (en) * | 1989-04-15 | 1989-06-01 | Scras Societe De Conseils De R | New 2-substituted n,n'-ditrimethoxybenzoyl piperazines |
FR2780649B1 (fr) * | 1998-07-06 | 2001-03-09 | Univ Paris Vii Denis Diderot | Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3318876A (en) * | 1962-12-11 | 1967-05-09 | Lepetit Spa | Substituted piperazines and process for preparing same |
GB1243991A (en) * | 1968-06-10 | 1971-08-25 | Ici Ltd | Piperidine, morpholine and piperazine derivatives |
FR2209560A1 (en) * | 1972-12-07 | 1974-07-05 | Degussa | N-(Trialkoxyaroyl)-ethylenediamine derivs - useful as cardioactive medicaments, exhibit anti-ischaemic activity comparable to nitroglycerin |
IT1194819B (it) * | 1980-11-20 | 1988-09-28 | Selvi & C Spa | Derivati della piperazina,procedimento per la loro preparazione e relative composizioni farmaceutiche |
GB8427735D0 (en) * | 1984-11-02 | 1984-12-12 | Fujisawa Pharmaceutical Co | Piperazine compound |
FR2581993B1 (fr) * | 1985-05-14 | 1988-03-18 | Synthelabo | Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique |
US4824996A (en) * | 1986-08-12 | 1989-04-25 | American Home Products Corporation | Phospholipase A2 inhibitors |
IL85700A0 (en) * | 1987-03-24 | 1988-08-31 | Takeda Chemical Industries Ltd | 1,4-disubstituted piperazine compounds,their production and use |
GB8823775D0 (en) * | 1988-10-11 | 1988-11-16 | Scras | New 2-carbonyl substituted n n'-di-(trimethoxybenzoyl)piperazines |
-
1988
- 1988-10-11 GB GB888823776A patent/GB8823776D0/en active Pending
-
1989
- 1989-09-29 CA CA000615180A patent/CA1319692C/en not_active Expired - Fee Related
- 1989-10-03 IN IN876DE1989 patent/IN173326B/en unknown
- 1989-10-04 ZA ZA897553A patent/ZA897553B/xx unknown
- 1989-10-06 CH CH3657/89A patent/CH679858A5/fr not_active IP Right Cessation
- 1989-10-06 NZ NZ230928A patent/NZ230928A/xx unknown
- 1989-10-06 US US07/418,113 patent/US4927825A/en not_active Expired - Lifetime
- 1989-10-09 GR GR890100646A patent/GR1000359B/el not_active IP Right Cessation
- 1989-10-09 SE SE8903313A patent/SE505222C2/sv not_active IP Right Cessation
- 1989-10-09 DZ DZ890158A patent/DZ1366A1/fr active
- 1989-10-10 MA MA21903A patent/MA21651A1/fr unknown
- 1989-10-10 NO NO894037A patent/NO176179C/no not_active IP Right Cessation
- 1989-10-10 LU LU87605A patent/LU87605A1/fr unknown
- 1989-10-10 BE BE8901088A patent/BE1003518A3/fr not_active IP Right Cessation
- 1989-10-10 PT PT91940A patent/PT91940B/pt not_active IP Right Cessation
- 1989-10-10 ES ES8903411A patent/ES2018404A6/es not_active Expired - Fee Related
- 1989-10-10 KR KR1019890014507A patent/KR970004913B1/ko not_active IP Right Cessation
- 1989-10-10 MY MYPI89001393A patent/MY105852A/en unknown
- 1989-10-10 DK DK500489A patent/DK500489A/da not_active Application Discontinuation
- 1989-10-10 TN TNTNSN89109A patent/TNSN89109A1/fr unknown
- 1989-10-10 AR AR89315125A patent/AR245111A1/es active
- 1989-10-10 AU AU42687/89A patent/AU619146B2/en not_active Ceased
- 1989-10-10 IE IE325789A patent/IE61621B1/en not_active IP Right Cessation
- 1989-10-11 FI FI894813A patent/FI96855C/fi not_active IP Right Cessation
- 1989-10-11 IT IT02199089A patent/IT1237087B/it active IP Right Grant
- 1989-10-11 FR FR8913259A patent/FR2637592B1/fr not_active Expired - Fee Related
- 1989-10-11 AT AT0234589A patent/AT395422B/de not_active IP Right Cessation
- 1989-10-11 NL NL8902519A patent/NL8902519A/nl not_active Application Discontinuation
- 1989-10-11 JP JP1263141A patent/JPH0635451B2/ja not_active Expired - Lifetime
- 1989-10-11 DE DE3933882A patent/DE3933882C2/de not_active Expired - Fee Related
- 1989-10-11 FR FR898913258A patent/FR2637499B1/fr not_active Expired - Fee Related
- 1989-10-11 OA OA59662A patent/OA09429A/xx unknown
- 1989-10-11 GB GB8922854A patent/GB2224027B/en not_active Expired - Fee Related
-
1992
- 1992-04-14 SG SG405/92A patent/SG40592G/en unknown
- 1992-07-02 HK HK474/92A patent/HK47492A/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9187434B2 (en) | Substituted 1,5-benzodiazepinones compounds | |
US9249157B2 (en) | Tricyclic heterocycle compounds | |
KR102659213B1 (ko) | Jak1 선택적 억제제 | |
CN109121414A (zh) | 苯并吡唑化合物和其类似物 | |
JP2021527666A (ja) | Wd40反復ドメインタンパク質5(wdr5)分解/破壊化合物および使用の方法 | |
JPWO2019189778A1 (ja) | 抗がん活性を有する化合物 | |
NO176179B (no) | Analogifremgangsmåte for fremstilling av nye terapeutisk aktive 2-substituerte N,N'-di(trimetoksybenzoyl)piperaziner | |
KR102537615B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
CA1320958C (en) | 2-carbonyl substituted n,n'-di-(trimethoxybenzoyl) piperazines, process for preparing the same and therapeutical compounds containing them | |
FR2645743A1 (fr) | Compositions therapeutiques a base de derives di-substitues des n,n(prime)-ditrimethoxybenzoyle piperazines | |
RU2809763C2 (ru) | Соединение, обладающее противораковой активностью |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |